📊 ZVRA Key Takeaways
Is Zevra Therapeutics, Inc.. (ZVRA) a Good Investment?
Zevra demonstrates exceptional revenue growth and maintains a fortress balance sheet with $95.6M cash and zero debt, positioning it well financially. However, a significant disconnect between reported net income ($37.9M) and operating cash flow ($6.1M) indicates earnings quality concerns, likely from non-operating gains or one-time items rather than sustainable operations.
Zevra Therapeutics, Inc.. Key Strengths (ZVRA)
- Exceptional revenue growth of 350.9% YoY demonstrates strong commercial execution
- Fortress balance sheet with $95.6M cash, no debt, and 4.89x current ratio provides financial flexibility
- Zero long-term debt and positive ROE/ROA indicate efficient capital structure
ZVRA Stock Risks: Zevra Therapeutics, Inc.. Investment Risks
- Major red flag: Net income ($37.9M) far exceeds operating cash flow ($6.1M), suggesting non-cash profits and earnings quality concerns
- Unusually high operating margin (144%) and net margin (104.6%) indicate likely one-time gains rather than sustainable profitability
- Small revenue base ($36.2M) typical of pharma companies carries regulatory, clinical trial, and competitive risks
Key Metrics to Watch
- Operating cash flow sustainability relative to net income in future periods
- Revenue growth trajectory and product pipeline contribution breakdown
- Clarification of non-operating gains and one-time items affecting profitability
Zevra Therapeutics, Inc.. (ZVRA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.89x current ratio provides a solid financial cushion.
ZVRA Profit Margin, ROE & Profitability Analysis
ZVRA vs Healthcare Sector: How Zevra Therapeutics, Inc.. Compares
How Zevra Therapeutics, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Zevra Therapeutics, Inc.. Stock Overvalued? ZVRA Valuation Analysis 2026
Based on fundamental analysis, Zevra Therapeutics, Inc.. appears fundamentally strong relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Zevra Therapeutics, Inc.. Balance Sheet: ZVRA Debt, Cash & Liquidity
ZVRA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Zevra Therapeutics, Inc..'s revenue has grown significantly by 272% over the 5-year period, indicating strong business expansion. The most recent EPS of $-2.28 indicates the company is currently unprofitable.
ZVRA Revenue Growth, EPS Growth & YoY Performance
ZVRA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $20.4M | -$3.1M | $-0.06 |
| Q3 2025 | $3.7M | -$544.0K | $-0.01 |
| Q2 2025 | $4.4M | -$3.1M | $-0.48 |
| Q1 2025 | $3.4M | -$3.1M | N/A |
| Q3 2024 | $2.9M | -$2.6M | N/A |
| Q2 2024 | $4.4M | -$2.6M | N/A |
| Q1 2024 | $3.2M | -$13.2M | N/A |
| Q3 2023 | $2.9M | -$1.9M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Zevra Therapeutics, Inc.. Dividends, Buybacks & Capital Allocation
ZVRA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Zevra Therapeutics, Inc.. (CIK: 0001434647)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ZVRA
What is the AI rating for ZVRA?
Zevra Therapeutics, Inc.. (ZVRA) has an AI grade of B with 62% confidence, based on fundamental analysis of SEC EDGAR filings.
What are ZVRA's key strengths?
Claude: Exceptional revenue growth of 350.9% YoY demonstrates strong commercial execution. Fortress balance sheet with $95.6M cash, no debt, and 4.89x current ratio provides financial flexibility.
What are the risks of investing in ZVRA?
Claude: Major red flag: Net income ($37.9M) far exceeds operating cash flow ($6.1M), suggesting non-cash profits and earnings quality concerns. Unusually high operating margin (144%) and net margin (104.6%) indicate likely one-time gains rather than sustainable profitability.
What is ZVRA's revenue and growth?
Zevra Therapeutics, Inc.. reported revenue of $36.2M.
Does ZVRA pay dividends?
Zevra Therapeutics, Inc.. does not currently pay dividends.
Where can I find ZVRA SEC filings?
Official SEC filings for Zevra Therapeutics, Inc.. (CIK: 0001434647) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ZVRA's EPS?
Zevra Therapeutics, Inc.. has a diluted EPS of $0.60.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is ZVRA's fundamental grade?
Based on our AI fundamental analysis in June 2026, Zevra Therapeutics, Inc.. has a B grade with 62% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is ZVRA stock overvalued or undervalued?
Valuation metrics for ZVRA: ROE of 18.4% (sector avg: 15%), net margin of 104.6% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
What is ZVRA's AI grade for 2026?
Our dual AI analysis gives Zevra Therapeutics, Inc.. a combined B grade for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is ZVRA's free cash flow?
Zevra Therapeutics, Inc..'s operating cash flow is $6.1M, with capital expenditures of $35.0K. FCF margin is 16.9%.
How does ZVRA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 104.6% (avg: 12%), ROE 18.4% (avg: 15%), current ratio 4.89 (avg: 2).